# EU-1-10-625_public-assessment-report_20100614_20100614_arzerra-epar-public-assessment-report.pdf

emes
European Medicines Agency
Evaluation of Medicines for Human Use
London, 20 January 2010
Doc.Ref .: EMA/CHMP/195135/2010
Medicinal Ineroduct plonger authorised
CHMP ASSESSMENT REPORT
Arzerra
International Nonproprietary Name: ofatumumab
Procedure No. EMEA/H/C/001131
Assessment Report as adopted by the CHMP with
all information of a commercially confidential nature deleted
7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 51
E-mail: mail@emea.europa.eu
http://www.emea.europa.eu
TABLE OF CONTENTS
1.
BACKGROUND INFORMATION ON THE PROCEDURE
1.1
Submission of the dossier
1.2
Steps taken for the assessment of the product.
2
SCIENTIFIC DISCUSSION
4
2.1
Introduction
4
2.2
Quality aspects
2.3
Non-clinical aspects
2.4
Clinical aspects
2.5
Pharmacovigilance
54
2.6
Overall conclusions, risk/benefit assessment and recommendation
59
3
3
3
5
10
21
Medicinal product no longer authorised
Page 2 of 63
